Form 4: Zimmer Biomet Director Maria Teresa Hilado Reports Acquisition of Phantom Stock Units and Restricted Stock Units

Director Maria Teresa Hilado reports acquisition of phantom stock units and restricted stock units in Zimmer Biomet Holdings, Inc.

Summary

• Maria Teresa Hilado, a director of Zimmer Biomet Holdings, Inc., filed a Form 4 disclosing changes in her beneficial ownership.
• On May 10, 2024, she acquired 616.726 phantom stock units at a price of $121.61.
• She also acquired 1,068.991 restricted stock units on the same date.
• Following these transactions, Hilado beneficially owns 8,233.114 phantom stock units and 6,173.928 restricted stock units.
• The phantom stock units will be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
• The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports routine stock acquisitions by a director. It doesn't indicate any significant positive or negative developments for the company.

Positives

• The acquisition of stock units by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The phantom stock units will be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date.

Industry Context

Directors' stock acquisitions are common in the healthcare industry, particularly in large companies like Zimmer Biomet. These acquisitions are often part of compensation packages designed to align the interests of management with those of shareholders.

Comparison to Industry Standards

• Stock ownership by directors is a common practice across publicly traded companies, including Zimmer Biomet's competitors such as Stryker Corporation (SYK) and Johnson & Johnson (JNJ).
• The vesting schedules and deferral periods for restricted stock units are also typical in executive compensation plans within the medical device industry.

Stakeholder Impact

• The reported transactions may have a minor positive impact on shareholder sentiment, as they reflect a director's investment in the company.

Key Dates